These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 26530367)

  • 41. New perspectives and strategy research biomarkers for hepatocellular carcinoma.
    Saffroy R; Pham P; Reffas M; Takka M; Lemoine A; Debuire B
    Clin Chem Lab Med; 2007; 45(9):1169-79. PubMed ID: 17635075
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma.
    Chon YE; Choi GH; Lee MH; Kim SU; Kim DY; Ahn SH; Kim KS; Choi JS; Han KH; Chon CY; Park JY
    Int J Cancer; 2012 Nov; 131(10):2332-41. PubMed ID: 22362471
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Peripheral blood microvesicles are potential biomarkers for hepatocellular carcinoma.
    Wang W; Li H; Zhou Y; Jie S
    Cancer Biomark; 2013; 13(5):351-7. PubMed ID: 24440975
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases.
    Lamerz R; Runge M; Stieber P; Meissner E
    Anticancer Res; 1999; 19(4A):2489-93. PubMed ID: 10470180
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Symptoms of hepatocellular carcinoma. Laboratory tests used for its diagnosis and screening].
    Gervain J
    Orv Hetil; 2010 Aug; 151(35):1415-7. PubMed ID: 20719715
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.
    Marrero JA; Su GL; Wei W; Emick D; Conjeevaram HS; Fontana RJ; Lok AS
    Hepatology; 2003 May; 37(5):1114-21. PubMed ID: 12717392
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fucosylated fraction of alpha-fetoprotein as a serological marker of early hepatocellular carcinoma.
    Moriya S; Morimoto M; Numata K; Nozaki A; Shimoyama Y; Kondo M; Nakano M; Maeda S; Tanaka K
    Anticancer Res; 2013 Mar; 33(3):997-1001. PubMed ID: 23482772
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Human telomerase reverse transcriptase messenger RNA (TERT mRNA) as a tumour marker for early detection of hepatocellular carcinoma.
    El-Mazny A; Sayed M; Sharaf S
    Arab J Gastroenterol; 2014 Jun; 15(2):68-71. PubMed ID: 25097049
    [TBL] [Abstract][Full Text] [Related]  

  • 49. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis.
    Liu Y; Hong Z; Tan G; Dong X; Yang G; Zhao L; Chen X; Zhu Z; Lou Z; Qian B; Zhang G; Chai Y
    Int J Cancer; 2014 Aug; 135(3):658-68. PubMed ID: 24382646
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical usefulness of alpha-1-antitrypsin in the diagnosis of hepatocellular carcinoma.
    Hong WS; Hong SI
    J Korean Med Sci; 1991 Sep; 6(3):206-13. PubMed ID: 1663767
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sublingual vein parameters, AFP, AFP-L3, and GP73 in patients with hepatocellular carcinoma.
    Zhao J; Guo LY; Yang JM; Jia JW
    Genet Mol Res; 2015 Jun; 14(2):7062-7. PubMed ID: 26125916
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current clinical uses of the biomarkers for hepatocellular carcinoma.
    Huang J; Zeng Y
    Drug Discov Ther; 2014 Apr; 8(2):98-9. PubMed ID: 24815586
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatocellular carcinoma surveillance: An evidence-based approach.
    Harris PS; Hansen RM; Gray ME; Massoud OI; McGuire BM; Shoreibah MG
    World J Gastroenterol; 2019 Apr; 25(13):1550-1559. PubMed ID: 30983815
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current and Emerging Tools for Hepatocellular Carcinoma Surveillance.
    Adeniji N; Dhanasekaran R
    Hepatol Commun; 2021 Dec; 5(12):1972-1986. PubMed ID: 34533885
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Present and future possibilities for early diagnosis of hepatocellular carcinoma.
    Stefaniuk P; Cianciara J; Wiercinska-Drapalo A
    World J Gastroenterol; 2010 Jan; 16(4):418-24. PubMed ID: 20101765
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HCC and Tumor Biomarkers: Does One Size Fits All?
    Ozgor D; Otan E
    J Gastrointest Cancer; 2020 Dec; 51(4):1122-1126. PubMed ID: 32827068
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Guideline compliant diagnostics of hepatocellular carcinoma].
    Plentz RR; Boozari B; Malek NP
    Radiologe; 2014 Jul; 54(7):660-3. PubMed ID: 24981446
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Contribution of biomarkers and imaging in the management of hepatocellular carcinoma.
    Fartoux L; Decaens T
    Clin Res Hepatol Gastroenterol; 2011 Jun; 35 Suppl 1():S21-30. PubMed ID: 21742297
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Surveillance for hepatocellular carcinoma in chronic liver disease: evidence and controversies.
    van Meer S; de Man RA; Siersema PD; van Erpecum KJ
    World J Gastroenterol; 2013 Oct; 19(40):6744-56. PubMed ID: 24187450
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Bayesian screening approach for hepatocellular carcinoma using multiple longitudinal biomarkers.
    Tayob N; Stingo F; Do KA; Lok ASF; Feng Z
    Biometrics; 2018 Mar; 74(1):249-259. PubMed ID: 28482112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.